Dynamk Capital

Dynamk Capital is a venture capital firm focused on investing in early-stage life sciences companies. The firm specializes in identifying and supporting innovative companies that develop disruptive technologies, tools, and services essential for the biopharmaceutical industry's discovery, development, and manufacturing processes. Their portfolio includes companies such as Alpenglow Biosciences, Virica Biotech, Vectron Biosolutions, Curibio, Lucid Scientific, Envisagenics, CellFE Biotech, and RoosterBio.

The firm's investment strategy centers on providing capital and strategic guidance to entrepreneurs commercializing innovative life science technologies. Dynamk Capital's team comprises experienced life science entrepreneurs, investors, advisors, and subject matter experts who offer engaged support to portfolio companies as they navigate commercialization and scaling. The firm invests from Seed through Series A, B, and growth stages, leveraging its extensive network to identify promising investment opportunities.

Dynamk Capital's commitment to the life sciences sector is evident through its active involvement in portfolio companies' growth and success. The firm has made 19 investments, with its most recent investment in CellFE on September 27, 2023. Their first fund, Dynamk Life Sciences Fund L.P., closed in April 2021 with total assets under management of $65 million. This fund focuses exclusively on enabling tools, technologies, and services critical to biopharma companies' needs, including cell and gene therapies and vaccines.